PBM ROLE IN Rx SWITCHING IS PROMOTIONAL CONCERN FOR FDA
PBM ROLE IN Rx SWITCHING IS PROMOTIONAL CONCERN FOR FDA, Division of Drug Marketing, Advertising & Communication Director Lucy Rose indicated during the Drug Information Association annual meeting June 8. FDA is interested in the promotional implications of pharmacists working to switch prescriptions. One question to consider, Rose suggested, "is whether 'switch' pharmacists are acting on behalf of the company, particularly if the company owns the pharmacy," as is the case with Merck/Medco and SmithKline/DPS.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth